Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer.
de Haan R, van den Heuvel MM, van Diessen J, Peulen HMU, van Werkhoven E, de Langen AJ, Lalezari F, Pluim D, Verwijs-Janssen M, Vens C, Schellens JHM, Steeghs N, Verheij M, van Triest B. de Haan R, et al. Among authors: de langen aj. Clin Cancer Res. 2021 Mar 1;27(5):1256-1266. doi: 10.1158/1078-0432.CCR-20-2551. Epub 2020 Dec 1. Clin Cancer Res. 2021. PMID: 33262140 Clinical Trial.
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C. Verhagen CV, et al. Among authors: de haan r. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. Radiother Oncol. 2015. PMID: 25981132
Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E, Hinsley S, Frangou E, Holmes J, de Haan R, Hawkins M, Brown S, Love SB. van Werkhoven E, et al. Among authors: de haan r. BMC Med Res Methodol. 2020 Jun 22;20(1):162. doi: 10.1186/s12874-020-01012-z. BMC Med Res Methodol. 2020. PMID: 32571298 Free PMC article.
Towards a national registry for Alzheimer's disease and related dementias: rationale, design, and initial observations of the ABOARD cohort.
de Boer C, Rhodius-Meester HFM, van der Landen SM, Claassen J, de Haan R, Papma JM, Seelaar H, Kloppenburg-Lagendijk M, van Munster B, de Vugt M, Arts D, Blom M, de Rijke TJ, Beusink M, Huijsman R, van Veen EB, van Harten A, Vijverberg J, Zwan M, Mutsaerts HJ, van der Lee SJ, van der Flier WM. de Boer C, et al. Among authors: de haan r. Alzheimers Res Ther. 2025 May 31;17(1):123. doi: 10.1186/s13195-025-01725-7. Alzheimers Res Ther. 2025. PMID: 40448198 Free PMC article.
409 results